Clinical Guides
Diabetic Retinopathy
A clinically focused guide to screening, grading and referral for diabetic retinopathy in India, integrating systemic risk reduction, retinal imaging, macular oedema and proliferative disease while keeping intravitreal, laser and surgical decisions within specialist services and stating local access limitations.
MedNext Academy | 12 min read
Diabetic Retinopathy
A clinically focused guide to screening, grading and referral for diabetic retinopathy in India, integrating systemic risk reduction, retinal imaging, macular oedema and proliferative disease while keeping intravitreal, laser and surgical decisions within specialist services and stating local access limitations.
Summary
Diabetic retinopathy is a neurovascular retinal complication of diabetes. Chronic metabolic and vascular injury causes microaneurysms, haemorrhages, capillary leakage and non-perfusion; progressive ischaemia may lead to retinal neovascularisation. Diabetic macular oedema can occur at any retinopathy stage and is a major cause of central visual loss. Early disease is often asymptomatic, so normal vision does not replace retinal screening. Sudden floaters, haze or visual loss may signal vitreous haemorrhage, while a field defect can indicate tractional or rhegmatogenous retinal detachment.
Clinical care has four connected tasks: ensure timely validated screening, classify retinal and macular disease, reduce modifiable systemic risk, and refer sight-threatening disease to an ophthalmologist experienced in retinal treatment. Fundus photography supports screening but does not automatically replace a dilated examination, optical coherence tomography or specialist assessment when images are ungradable or abnormalities are present. Glycaemia, blood pressure, lipids, kidney disease, pregnancy and the speed of metabolic improvement affect risk and follow-up.
Treatment is stage- and eye-specific. Options include observation with planned imaging, panretinal photocoagulation, intravitreal anti-vascular endothelial growth factor therapy, focal or grid laser in selected macular disease, corticosteroid therapy in selected eyes and vitrectomy for defined complications. Adherence and capacity for repeated visits influence choice. This guide does not prescribe an injection, create an Indian national treatment algorithm or certify image grading. It remains reviewed and has been reviewed by the MedNext Clinical Team.
How Common Is It?
The number of people at risk rises with diabetes prevalence and survival, but diabetic retinopathy frequency cannot be represented by one timeless Indian percentage. Estimates depend on diabetes type, duration, age, glycaemic exposure, pregnancy, kidney disease, whether the sample is community- or clinic-based, and whether diagnosis uses direct examination, dilated photography or another grading method. Studies that count any microaneurysm are not comparable with those reporting sight-threatening retinopathy. This guide therefore avoids extrapolating a regional study to the whole country.
Risk accumulates with duration. Retinopathy may already be present when type 2 diabetes is diagnosed because hyperglycaemia often preceded recognition, whereas the timing in type 1 diabetes is usually linked more clearly to onset. Diabetic macular oedema can impair central vision before proliferative change, and proliferative disease may remain unnoticed until bleeding occurs. The absence of symptoms is consequently a weak reassurance.
India's NPCBVI explicitly includes diabetic retinopathy among common blinding disorders, and the national primary eye-care operational framework places screening and referral within vision-centre and higher-facility pathways. This establishes programme relevance, not uniform delivery. Camera availability, trained graders, pupil dilation, retina services, travel and follow-up vary by district. A useful local burden measure reports the eligible diabetes population, screened proportion, ungradable images, grades referred, treatment uptake and visual outcomes rather than only the number photographed.
Risk Factors
Longer diabetes duration and greater cumulative hyperglycaemia are the strongest clinical predictors. Hypertension, dyslipidaemia and diabetic kidney disease are associated with progression, and smoking increases overall vascular harm even where its independent retinopathy effect is less simple. Puberty and pregnancy can accelerate disease. A person with previous poor attendance, established retinopathy in either eye, rapid HbA1c improvement, anaemia or other microvascular complications deserves particular attention to follow-up planning.
Both type 1 and type 2 diabetes confer risk. Type 2 disease may have been biologically present before diagnosis, which is why retinal assessment is recommended at diagnosis. In type 1 diabetes, the first routine examination occurs after a defined duration in international guidance, but children and adolescents follow age- and puberty-specific pathways. Pregnancy planning requires a retinal status check; gestational diabetes alone does not carry the same established retinopathy pathway as pre-existing diabetes.
Risk modification is not equivalent to chasing an identical target for every patient. Glycaemic, blood-pressure and lipid goals must account for age, hypoglycaemia, kidney disease, cardiovascular risk and treatment burden. Rapid improvement in glucose can transiently worsen existing retinopathy, so eye status and follow-up should be considered when intensifying therapy, including in people receiving glucose-lowering agents associated with large early HbA1c reductions. None of these risk factors permits a non-ophthalmologist to infer retinal grade without examination or validated images.
Diagnosis
History
Record diabetes type, onset or diagnosis date, recent and historical glycaemic control, blood pressure, lipids, kidney disease, pregnancy or plans for pregnancy, medicines and attendance at previous eye screening. Ask about blur, distortion, reading difficulty, impaired colour or contrast, floaters, haze, flashes, field loss and sudden change. Early retinopathy can produce no symptoms. Establish previous laser, injections or surgery, treatment response, the last retinal grade and ability to attend repeated visits.
Examination
Measure monocular visual acuity with current correction and pinhole, pupils, anterior segment and intraocular pressure. Dilated retinal examination assesses both eyes for microaneurysms, intraretinal haemorrhages, venous changes, cotton-wool spots, intraretinal microvascular abnormalities, neovascularisation, preretinal or vitreous haemorrhage, fibrovascular proliferation and detachment. Inspect the macula for thickening or exudates. A normal undilated direct view does not constitute a complete screening episode, and cataract may make images ungradable.
Investigations
Validated retinal photography with trained grading is suitable for screening and teleophthalmology. Optical coherence tomography measures retinal thickness and morphology when macular oedema is suspected or monitored. Fluorescein angiography may define leakage, non-perfusion or neovascularisation when it changes specialist management; it is not routine for every screen. B-scan ultrasound helps when media opacity or haemorrhage prevents fundus visualisation. Review HbA1c, blood pressure, lipids, renal function and urine albumin data with the diabetes team. Grade severity and image quality explicitly, document the referral interval, and never label an ungradable image normal.
Differential Diagnosis
Retinal microaneurysms and haemorrhages are not automatically diabetic. Hypertensive retinopathy can produce arteriolar narrowing, arteriovenous crossing changes, flame haemorrhages, cotton-wool spots and disc swelling in severe disease. Retinal vein occlusion is often sectoral or diffuse with venous dilation and haemorrhage. Radiation retinopathy, sickle-cell retinopathy, ocular ischaemic syndrome and inflammatory retinal vasculitis can mimic capillary non-perfusion or neovascularisation. The pattern, systemic history and angiographic findings help separate them.
Central blur in a person with diabetes may arise from cataract, uncorrected refractive error, age-related macular degeneration, epiretinal membrane, macular hole, central serous chorioretinopathy or optic neuropathy rather than diabetic macular oedema. Optical coherence tomography clarifies retinal architecture, but interpretation must match symptoms and examination. Sudden loss may be caused by retinal artery or vein occlusion, retinal detachment, vitreous haemorrhage, optic neuropathy or neurological disease.
White retinal lesions, hard exudates and cotton-wool spots describe appearances rather than diagnoses. Severe anaemia, blood dyscrasia and infection can create related findings. Retinopathy from pre-existing diabetes in pregnancy must be distinguished from hypertensive disorders of pregnancy. A cataract can obscure the retina but should not justify assuming that the posterior segment is healthy. If photography is ungradable, arrange repeat imaging with dilation or examination through an appropriate pathway rather than closing screening as negative.
Management
Coordinate systemic and ocular care. Help the person reach individualized glycaemic, blood-pressure and lipid goals, manage kidney and cardiovascular risk, and support smoking cessation without suggesting that systemic control reverses advanced neovascular disease. Explain that early retinopathy may remain symptom-free and that treatment aims mainly to prevent further loss. Record which service owns the next retinal review; vague advice to attend annually is unsafe when sight-threatening findings need weeks or days.
For non-proliferative retinopathy without centre-involving oedema, management may be monitoring with a frequency based on severity, image quality, systemic risk and progression. Proliferative retinopathy generally requires prompt retina assessment. Panretinal photocoagulation remains an established treatment; intravitreal anti-VEGF can be an alternative in selected eyes when reliable repeated attendance is feasible. Choice considers pregnancy, traction, baseline vision, fellow-eye status, treatment burden and local capability.
Most eyes with centre-involving diabetic macular oedema and impaired acuity are considered for anti-VEGF therapy. Selected non-centre-involving oedema, persistent disease or eyes unsuitable for first-line injections may be managed with focal or grid laser, corticosteroid options or observation under specialist protocols. Vitrectomy is considered for non-clearing vitreous haemorrhage, tractional detachment threatening the macula or other surgical indications. Never improvise an injection or laser schedule from a summary. Confirm response, adverse effects, missed-visit contingency and re-entry to screening after specialist discharge.
Prescribing Information
Intravitreal anti-VEGF medicines and intraocular corticosteroid implants are specialist-administered treatments, not routine outpatient prescriptions. Selection, consent, aseptic injection technique, laterality, product, interval and stopping or switching criteria belong to a retina service. Anti-VEGF therapy can require repeated visits; loss to follow-up is especially hazardous in proliferative disease controlled by injections alone. Pregnancy requires individual risk-benefit discussion because systemic fetal safety evidence is limited. Cardiovascular history and recent vascular events should be considered according to the product information and specialist judgement.
Intraocular corticosteroid therapy can raise intraocular pressure and accelerate cataract, so lens status, glaucoma risk and pressure monitoring matter. Laser is a procedure rather than a drug: panretinal treatment can reduce peripheral or night vision and may worsen macular oedema, while focal or grid treatment is reserved for selected macular patterns. Aspirin prescribed for cardiovascular indications should not be stopped merely because retinopathy is present; the ADA states retinopathy is not a contraindication to cardioprotective aspirin.
Systemic glucose, blood-pressure and lipid medicines are individualized by the diabetes team. Do not pursue abrupt glucose lowering solely for an eye finding without coordinating follow-up, because rapid improvement can be associated with early worsening in susceptible patients. Record all ocular injections, laser sessions, drops and systemic agents. The guide intentionally gives no injection dose or brand hierarchy because availability, approval, indication, cost and evidence evolve and patient-specific prescribing requires specialist review.
When to Refer
Promptly refer any diabetic macular oedema, moderate or worse non-proliferative retinopathy, suspected proliferative retinopathy, retinal neovascularisation, preretinal or vitreous haemorrhage, unexplained visual reduction or ungradable retinal images through an ophthalmic pathway. Referral urgency is shortest for new vessels, haemorrhage, traction threatening the macula, retinal detachment or acute visual change. State acuity, symptoms, retinal grade in each eye, macular status, image quality, diabetes duration, HbA1c trend, blood pressure, renal disease, pregnancy and prior ocular treatment.
A screening programme is not a treatment service. If an abnormal photograph is found, responsibility must transfer clearly, with appointment, destination and safety-net. If a patient misses an injection, laser or retina review, active recall is preferable to simply returning them to routine screening. People with normal screening still require the next evidence-based interval; type 2 diabetes starts retinal assessment at diagnosis, while type 1 timing and paediatric intervals follow current diabetes guidance.
Same-day emergency ophthalmology is appropriate for sudden severe visual loss, a new field curtain, dense new floaters or haze, flashes with field change, suspected retinal detachment, painful red eye after injection or surgery, or neurological features. Pregnancy with pre-existing diabetes requires planned eye assessment and closer follow-up if retinopathy exists. In India, select the actual accessible retina service and anticipate travel, cost, language and repeated-visit requirements before choosing a pathway.
Red Flags
Sudden painless loss of vision, a sudden shower of floaters, dark haze or a curtain across the visual field may indicate vitreous haemorrhage or retinal detachment. New vessels can bleed without warning. These symptoms require urgent dilated retinal assessment, not a routine screening appointment. Pain, redness, photophobia, discharge or reduced vision after an intravitreal injection raises concern for endophthalmitis and is an ophthalmic emergency. Severe headache, focal neurological deficit or transient monocular loss requires broader vascular and neurological assessment.
High-risk examination findings include neovascularisation of the disc or elsewhere, preretinal or vitreous haemorrhage, fibrovascular traction, macula-threatening detachment, extensive non-perfusion, marked centre-involving oedema or an image that cannot be graded despite appropriate attempts. Iris or angle neovascularisation with raised pressure can produce painful neovascular glaucoma. A normal acuity value does not neutralise these signs.
Systemic red flags include pregnancy with active proliferative disease, rapidly changing glycaemia in someone with advanced retinopathy, severe hypertension, acute kidney deterioration or inability to attend essential treatment. Bilateral simultaneous visual decline threatens medication use, mobility and employment and needs social as well as clinical support. Never reassure solely because diabetes is described as controlled today; retinal damage reflects cumulative exposure. Conversely, do not diagnose diabetic retinopathy from diabetes plus blur without examining the retina and excluding cataract, refractive and neurological causes.
Indian Clinical Context
The 2020 Government of India Operational Guidelines for Primary Eye Care at Health and Wellness Centres place diabetic-retinopathy screening and facilitated specialist consultation within referral-centre and vision-centre services. The document describes annual eye examination for a person with diabetes and non-mydriatic fundus photography where available. That operational expectation should be implemented with trained acquisition, validated grading, a route for ungradable images, documented referral completion and access to treatment; a camera without those components is not a screening programme.
NPCBVI recognizes diabetic retinopathy as a priority blinding disorder, but retina capacity varies. Some districts use medical colleges, district hospitals, mobile imaging or teleophthalmology; intravitreal treatment, laser and vitrectomy may require travel to a higher centre. Cost includes repeated visits and lost work, not only the procedure. Treatment choice must consider whether follow-up is realistically sustainable, while avoiding a lower standard simply because the patient has fewer resources.
ADA and international guidelines recommendations are international evidence sources, not Indian legal protocols. current guidelines focuses on people already under hospital eye services and explicitly does not define routine population screening. This guide does not assert a national Indian prevalence, a universal injection formulary or equal service availability. Clinicians should reconcile state pathways, current product approvals, institutional retina protocols and individual needs. Clear bilingual counselling, referral tracking and coordination between diabetes and eye services are high-value actions across settings.
NMC Competency Mapping
NMC ophthalmology competencies OP8.2, OP8.3 and OP8.4 provide the principal retina mapping. OP8.2 requires learners to enumerate laser indications in retinal disease, explicitly including diabetic retinopathy. OP8.3 requires correct fundus-examination technique and distinction between normal and abnormal retinal findings. OP8.4 covers retinal treatment modalities. General medicine competency IM11.7 addresses chronic complications of diabetes and provides horizontal integration, but ophthalmic examination and treatment remain within supervised eye-care training.
A competent undergraduate should explain why screening precedes symptoms, identify microaneurysms, dot-and-blot haemorrhages, hard exudates, cotton-wool spots, venous change, intraretinal microvascular abnormalities and new vessels, and separate non-proliferative from proliferative disease. The learner should recognise that macular oedema can occur at any stage, document visual acuity and understand when photography, dilation, OCT, angiography or ultrasonography is used.
Management knowledge includes systemic risk reduction, monitoring, panretinal photocoagulation, anti-VEGF therapy, selected focal or grid laser, corticosteroid options and vitrectomy indications. It does not confer competence to grade independently, inject or laser. Assessment should test referral urgency, image quality, follow-up ownership, pregnancy and access barriers, not only lesion recall. Curricular mapping is educational and does not replace current retina-service protocols or supervised procedural certification.
Key Exam Pearls for NEET PG
Microaneurysms are an early visible lesion. Non-proliferative disease progresses through increasing haemorrhage, venous abnormalities and intraretinal microvascular abnormalities; proliferative retinopathy is defined by neovascularisation. New vessels are fragile and cause preretinal or vitreous haemorrhage. Fibrovascular contraction can produce tractional retinal detachment. Diabetic macular oedema can occur at any retinopathy stage and is a major cause of central visual loss. Hard exudates represent lipid deposition, while cotton-wool spots reflect nerve-fibre-layer microinfarction.
Screen at diagnosis in type 2 diabetes because disease may have preceded recognition. International adult guidance starts routine examination after a period of type 1 diabetes, with paediatric and pregnancy pathways handled separately. A normal acuity test does not exclude retinopathy. Fundus photography requires gradable images and a qualified interpretation route; OCT is central to macular-oedema assessment but does not replace peripheral retinal examination. Fluorescein angiography demonstrates leakage and non-perfusion when management requires it.
Panretinal photocoagulation is established for high-risk proliferative disease. Anti-VEGF is first-line for most centre-involving oedema with impaired acuity and can be an alternative for selected proliferative disease when repeated follow-up is reliable. Vitrectomy is used for selected non-clearing haemorrhage and tractional complications. Optimize glycaemia, pressure and lipids, but remember that rapid glucose improvement can initially worsen retinopathy. Sudden floaters or visual loss, new vessels, vitreous haemorrhage and macula-threatening traction demand urgent retina referral.
Frequently Asked Questions
Can diabetic retinopathy be present when vision is still normal?
Yes. Early and even clinically important retinal changes may be asymptomatic, and high-contrast acuity can remain normal away from the macula. Screening with a validated retinal pathway is therefore necessary even when the person has no visual complaint. An ungradable photograph is not a negative screen and needs repeat imaging or examination.
When should retinal screening begin after diabetes is diagnosed?
Current ADA adult guidance recommends a comprehensive eye examination at diagnosis for type 2 diabetes and five years after onset for type 1 diabetes, with separate age-specific advice for children and closer planning in pregnancy. Indian operational guidance expects regular, generally annual eye assessment, but the next interval must reflect retinal findings, progression and the local programme.
Does better glucose control remove established diabetic retinopathy?
No. Achieving individualized glucose, blood-pressure and lipid goals reduces future risk and can slow progression, but it does not replace retinal treatment when macular oedema or proliferative disease is present. Rapid glucose improvement can initially worsen existing retinopathy in susceptible people, so retinal status and follow-up should be coordinated during major treatment intensification.
Which visual symptoms in diabetes require urgent eye assessment?
Sudden visual loss, a shower of new floaters, dark haze, flashes with a curtain or field defect, or pain and redness after an eye injection or operation require urgent ophthalmic assessment. They may represent vitreous haemorrhage, retinal detachment, vascular occlusion, acute pressure rise or infection rather than routine gradual diabetic change.
Inside MedNext for this topic
- 411 MedNext-authored chapters
- 80,000+ MCQ bank
- 15 study modes
- a growing library of visual revision sheets
Study modes
- Notes
- MCQ
- Audio
- Video
- Visual
- 3D Anatomy
- Trace
- Flashcards
- Mnemonics
- Image Bank
- Clinical
- Microscopy
- Audio QBank
- Cadaver
- Book Match
Continue reading
Clinical GuidesAll Clinical Guides
Browse all clinical management guides for Indian medical practice.
Test your knowledge
Attempt structured MCQs on this topic to consolidate your understanding and connect the guide to exam-focused practice.
Try MCQs on this topic